Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Matthew Krebs; Rajiv Shinde; Rozana Rahman; Rafael Grochot; Martin Little; Joseph Kitchin; Mona Parmar; Alison Turner; Muneeb Mahmud; Christina Yap; Nina Tunariu; Juanita Lopez; Johann Bono; Udai Banerji; Anna Minchom

doi:10.1158/1538-7445.AM2021-CT019

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Matthew Krebs, Rajiv Shinde, Rozana Rahman, Rafael Grochot, Martin Little, Joseph Kitchin, Mona Parmar, Alison Turner, Muneeb Mahmud, Christina Yap, Nina Tunariu, Juanita Lopez, Johann Bono, Udai Banerji, Anna Minchom

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Journal	Cancer Research
Volume	81
DOIs	https://doi.org/10.1158/1538-7445.AM2021-CT019
Publication status	Published - 1 Jul 2021

Access to Document

10.1158/1538-7445.AM2021-CT019

Cite this

Krebs, M., Shinde, R., Rahman, R., Grochot, R., Little, M., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., Yap, C., Tunariu, N., Lopez, J., Bono, J., Banerji, U., & Minchom, A. (2021). Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC. Cancer Research, 81. https://doi.org/10.1158/1538-7445.AM2021-CT019

@article{95b4667c837c4f1091dea1bb652c44d2,

title = "Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC",

author = "Matthew Krebs and Rajiv Shinde and Rozana Rahman and Rafael Grochot and Martin Little and Joseph Kitchin and Mona Parmar and Alison Turner and Muneeb Mahmud and Christina Yap and Nina Tunariu and Juanita Lopez and Johann Bono and Udai Banerji and Anna Minchom",

year = "2021",

month = jul,

day = "1",

doi = "10.1158/1538-7445.AM2021-CT019",

language = "English",

volume = "81",

journal = "Cancer Research",

issn = "1538-7445",

publisher = "American Association for Cancer Research",

}

Krebs, M, Shinde, R, Rahman, R, Grochot, R, Little, M, Kitchin, J, Parmar, M, Turner, A, Mahmud, M, Yap, C, Tunariu, N, Lopez, J, Bono, J, Banerji, U & Minchom, A 2021, 'Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC', Cancer Research, vol. 81. https://doi.org/10.1158/1538-7445.AM2021-CT019

TY - JOUR

T1 - Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

AU - Krebs, Matthew

AU - Shinde, Rajiv

AU - Rahman, Rozana

AU - Grochot, Rafael

AU - Little, Martin

AU - Kitchin, Joseph

AU - Parmar, Mona

AU - Turner, Alison

AU - Mahmud, Muneeb

AU - Yap, Christina

AU - Tunariu, Nina

AU - Lopez, Juanita

AU - Bono, Johann

AU - Banerji, Udai

AU - Minchom, Anna

PY - 2021/7/1

Y1 - 2021/7/1

U2 - 10.1158/1538-7445.AM2021-CT019

DO - 10.1158/1538-7445.AM2021-CT019

M3 - Meeting Abstract

SN - 1538-7445

VL - 81

JO - Cancer Research

JF - Cancer Research

ER -